GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Eupraxia Pharmaceuticals EPRX.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

10.46

+7.72%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$54.0m

FY2017FY2025

Free cash flow

−$40.8m

FY2017FY2025

Shareholders' equity

$112.7m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross profit−$332,889−$163,473−$158,047−$193,273−$111,529−$116,809−$201,936−$125,826−$85,376
Research and development$29.6m$15.2m$21.0m$17.6m$10.2m$1.1m$3.4m$6.8m$3.3m
Operating income−$53.8m−$25.7m−$28.6m−$22.9m−$22.1m−$2.1m−$5.8m−$12.1m−$4.9m
Net income−$54.0m−$24.3m−$28.2m−$23.3m−$23.0m−$4.0m−$7.2m−$13.2m−$4.3m
Diluted earnings per share-1.04-0.68-1.03-1.08-1.85-0.31-0.56-1.03-0.34

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$118.3m$34.9m$20.1m$25.9m$31.2m$1.5m$3.3m$2.9m$5.8m
Cash and short-term investments$110.7m$33.1m$19.3m$24.7m$29.9m$150,130$1.2m$823,481$4.0m
Total liabilities$7.8m$3.1m$19.2m$14.5m$11.7m$23.1m$21.4m$14.3m$735,815
Debt$215,745—$10.4m$10.6m$9.6m$17.8m$16.9m$10.6m$10,000
Shareholders' equity$112.7m$33.4m$2.2m$12.9m$20.4m−$21.2m−$17.7m−$11.1m$6.0m
Shares outstanding52m36m27m22m12m13m13m13m13m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$40.0m−$30.0m−$21.0m−$25.8m−$20.2m−$555,911−$5.2m−$8.3m−$5.3m
Capital spending−$824,740−$104,227−$55,247−$424,399−$594,097−$4−$9,479−$141,856−$314,689
Free cash flow−$40.8m−$30.1m−$21.1m−$26.3m−$20.7m−$555,915−$5.2m−$8.5m−$5.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit−$180,912−$122,029−$101,739−$89,201−$77,489−$46,836−$52,973−$51,047
Operating income−$24.3m−$21.6m−$22.6m−$9.5m−$11.4m−$7.1m−$7.5m−$6.3m
Net income−$19.4m−$17.1m−$23.4m−$8.8m−$12.0m−$6.8m−$7.5m−$5.9m
Diluted earnings per share-0.29-0.26-0.45-0.17-0.23-0.13-0.21-0.17
Cash from operations−$17.0m−$13.0m−$13.0m−$4.0m−$11.0m−$8.0m−$8.0m−$7.0m
Total assets$192.2m$200.2m$118.3m$126.8m$32.5m$29.2m$34.9m$10.4m
Cash and short-term investments$183.7m$191.3m$110.7m$122.1m$27.2m$27.5m$33.1m$6.4m
Debt$219,674$560,365$215,745$209,067$96,414$105,855$143,674$157,147
Shareholders' equity$180.4m$189.8m$112.7m$123.6m$31.0m$28.6m$33.4m$7.0m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income33.0%90.8%—
Net income32.4%68.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-7.2-4.8-3.8-2.5-1.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.